01:07 AM EDT, 08/27/2026 (MT Newswires) -- Lytix Biopharma (LYTIX.OL) agreed to participate in an investigator-initiated phase 2 trial of a combination formulation to treat early-stage resectable melanoma. The clinical-stage immuno-oncology company will team up with the Netherlands Cancer Institute, European Institute of Oncology, and eight Dutch and Italian melanoma expert centers in the multi-arm Aletta study, which will assess ruxotemitide with ipilimumab plus nivolumab and pembrolizumab in patients with resectable stage 3 melanoma, according to a Wednesday release. The study is expected to involve more than 260 patients, with enrollment for the ipilimumab/nivolumab plus ruxotemitide comparison expected to start in early 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.